NewsNovo
The case for Liminatus Pharma, Inc. staying on Nasdaq grows thinner by the week.
The Fullerton, California pharmaceutical company disclosed on July 24, 2026, that the exchange has notified it the company failed to regain compliance with the minimum $1 bid price requirement and is no longer eligible for a second 180-day extension, placing its Class A common stock (LIMN) and warrants (LIMNW) in jeopardy ahead of a Nasdaq Hearings Panel decision that has not yet been issued.
How the compliance clock ran out Liminatus Pharma first received a deficiency notice from the Nasdaq Listing Qualifications Department on January 15, 2026.
The notice stated the company's closing bid price had fallen below $1 per share for 30 consecutive business days, triggering Nasdaq Listing Rule 5450(a)(1).
Keep reading